Vasopressin Receptor

亜型選択性的な製品

Vasopressin receptor 1 Vasopressin receptor 2

シグナル伝達経路

Vasopressin Receptor製品

All (6)
Vasopressin Receptor拮抗剤(6)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S2593	Tolvaptan	Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.	J Immunother Cancer, 2024, 12(11)e009805 Acta Physiol (Oxf), 2021, 10.1111/apha.13661 J Mol Cell Biol, 2020, 12(8):644-653
S2116	Conivaptan HCl	Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.	J Immunother Cancer, 2024, 12(11)e009805 Cell Res, 2022, 1-17 Antimicrob Agents Chemother, 2017, AAC.01674-17
S2920	Mozavaptan	Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.	Life Sci, 2019, 10.1016/j.lfs.2019.05.049 Am J Med Sci, 2019, 357(3):247-254
S0007	RO 5028442 (RG7713)	RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815	Lixivaptan (VPA-985)	Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957^New	Mozavaptan (hydrochloride)	Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
S2593	Tolvaptan	Tolvaptan (OPC-41061) is an orally effective nonpeptide arginine vasopressin V2 receptor antagonist with IC50 of 3 nM, used to treat hyponatremia.	J Immunother Cancer, 2024, 12(11)e009805 Acta Physiol (Oxf), 2021, 10.1111/apha.13661 J Mol Cell Biol, 2020, 12(8):644-653
S2116	Conivaptan HCl	Conivaptan HCl(YM 087) is an orally active, non-peptide, vasopressin V1A and V2 receptor antagonist, used in the treatment of euvolemic and hypervolemic hyponatremia.	J Immunother Cancer, 2024, 12(11)e009805 Cell Res, 2022, 1-17 Antimicrob Agents Chemother, 2017, AAC.01674-17
S2920	Mozavaptan	Mozavaptan (OPC-31260) is a novel competitive vasopressin receptor antagonist for both V1 and V2 receptors with IC50 of 1.2 μM and 14 nM, respectively.	Life Sci, 2019, 10.1016/j.lfs.2019.05.049 Am J Med Sci, 2019, 357(3):247-254
S0007	RO 5028442 (RG7713)	RO 5028442 (RG7713) is a highly potent and selective Brain-Penetrant Vasopressin 1a (V1a) receptor antagonist with Kis of 1 nM for hV1a and 39 nM for mV1a.
S2815	Lixivaptan (VPA-985)	Lixivaptan (VPA-985, CRTX 080, WAY VPA 985) is an oral, non-peptide, selective V2 receptor vasopressin antagonist with IC50s of 1.2 nM and 2.3 nM for human V2 receptor and rat V2 receptor, respectively.
E4957^New	Mozavaptan (hydrochloride)	Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.
E4957^New	Mozavaptan (hydrochloride)	Mozavaptan hydrochloride(OPC 31260 HCl), a benzazepine derivative is a potent, selective, competitive, and orally active antagonist of vasopressin V2 receptor with an IC50 value of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment.

Vasopressin Receptor阻害剤の選択性比較

Tags: Vasopressin Receptor inhibitor|Vasopressin Receptor agonist|Vasopressin Receptor activator|Vasopressin Receptor inducer|Vasopressin Receptor antagonist|Vasopressin Receptor signaling pathway|Vasopressin Receptor assay kit